Substantial numbers of C19 patients are being given HCQ in C19 trials, but more than that, substantial numbers of newly-diagnosed C19 patients are already taking HCQ, since it's part of the standard of care for widespread conditions like rheumatoid arthritis. And those patients will of course have had the HCQ intervention before acquiring C19, not late in the course of their illness. It doesn't look like anyone is reporting unusual clinical success for those patients, while you can find clinical reports of QT disturbances (so: people are paying attention to this stuff).
Based on my experience, the standard dosage for rheumatoid arthritis is 400 mg/day vs 600 mg/day for COVID-19. To start with, anyway. I opted for 200 mg/day, and my rheumatologist concurred.
